Latest News - Movement Disorders

Thursday, September 14, 2017 | Movement Disorders, Research and Publications, Genentech

17 New Genes Linked to Parkinson’s Disease

A new study has discovered 17 novel genetic variants associated with Parkinson’s disease, several of which are considered targets for intervention. Published in Nature Genetics, the genome-wide …

Read the full story

Thursday, August 31, 2017 | FDA Approval/Clearance, Movement Disorders

Austedo Approved for Treatment of Tardive Dyskinesia

The FDA has approved Austedo (deutetrabenazine, Teva Pharmaceutical Industries Ltd.) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two Phase 3 …

Read the full story

Tuesday, August 29, 2017 | Business of Medicine, Clinical Trials, Movement Disorders, Research and Publications

AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent

AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s…

Read the full story

Thursday, July 13, 2017 | Movement Disorders

Sage Bionetworks Launches DREAM Challenge to Identify Best Uses for Remote Sensing Devices

Sage Bionetworks has launched the Parkinson’s Disease Digital Biomarker DREAM Challenge, the first in a series of open, crowd-sourced analytical projects to help researchers identify ways to use…

Read the full story

Wednesday, July 12, 2017 | Movement Disorders, Research and Publications

Visual System Changes May Represent an Early Signal of Parkinson’s Disease

Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated 21 patients with newly d…

Read the full story

Wednesday, June 14, 2017 | Movement Disorders, Phase 3/4 Trials, Research and Publications

Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment

Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (L…

Read the full story

Friday, June 09, 2017 | Movement Disorders, Research and Publications

Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT

PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presente…

Read the full story

Wednesday, June 07, 2017 | Movement Disorders, Research and Publications

Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease

Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Dis…

Read the full story

Tuesday, May 30, 2017 | Dementia & Cognitive Disorders, Movement Disorders, Research and Publications

Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells

Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently pu…

Read the full story

Wednesday, April 26, 2017 | Movement Disorders, Research and Publications

AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut

Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of…

Read the full story

Monday, April 24, 2017 | Movement Disorders, Personnel/Company News, Research and Publications

Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS

Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting&…

Read the full story

Wednesday, April 12, 2017 | FDA Approval/Clearance, Movement Disorders, Product Launches and Updates

First Treatment for Tardive Dyskinesia Approved in US

The FDA approved the selective VMAT2 inhibitor Ingrezza (valbenazine, Neurocrine Biosciences), making it the first treatment approved in the US to treat adults with tardive dyskinesia. The efficacy of…

Read the full story

Tuesday, April 04, 2017 | FDA Approval/Clearance, Movement Disorders, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials

New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval

The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for th…

Read the full story

Wednesday, March 22, 2017 | FDA Approval/Clearance, Movement Disorders

Novel Adjunct Agent Approved for Parkinson’s "Off" Periods

The FDA approved Xadago (safinamide, Newron Pharmaceuticals) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing &ld…

Read the full story

Friday, February 10, 2017 | Movement Disorders, Phase 3/4 Trials

Inhaled Levodopa Impresses in Treating Parkinson’s OFF Periods in Phase 3 Study

New phase 3 data suggests that the experimental inhaled levodopa, CVT-301 (Acorda Therapeutics), may offer significant improvement in motor function in individuals with Parkinson’s disease exper…

Read the full story
Load More